CEP55 and lung adenocarcinoma: Exploring the differences in the molecular mechanisms of CEP55 in LUAD and LUSC is beneficial to further explore the new NSCLC targeted diagnostic approach, which is helpful for the effectiveness of anticancer therapy, thereby improving the overall survival rate of lung adenocarcinoma of lung cancer.